Literature DB >> 11762691

Effects of acamprosate and scopolamine on the working memory of rats in a three-panel runway task.

I Okulicz-Kozaryn1, P Midolajczak, K Szczawinska, E Kaminska, K Kus.   

Abstract

The aim of this study was to evaluate the effect of treatment with single (1x) and multiple (10x) doses of the anti-craving compound acamprosate (AC, calcium acetyl homotaurinate) on working memory in rats, using in a three-panel runway test. We measured tasks after the animals were treated with AC (500 mg/kg/d, i.p.); scopolamine (SC, 0.5 mg/kg/d, i.p.), a cholinergic muscarinic receptor antagonist; or both drugs concomitantly (ACSC), either for 1 day (1x) or daily for 10 consecutive days (10x). Neither 1x not 10x AC alone had a significant effect on working memory task performance, whereas treatment with SC alone had a significantly negative effect on the ability of the rats to complete the tasks. Rats receiving ACSC performed better than those receiving SC alone, making fewer errors and displaying shorter latency, similar to the performance of the control group. These observations support the hypothesis of an indirect involvement of AC in the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762691     DOI: 10.1515/jbcpp.2001.12.3.197

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  3 in total

1.  Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice.

Authors:  Danielle Gulick; Thomas J Gould
Journal:  Neurobiol Learn Mem       Date:  2008-04-14       Impact factor: 2.877

2.  The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine.

Authors:  Andrew J McGeehan; M Foster Olive
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 3.  Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal.

Authors:  Tamzin L Ripley; David N Stephens
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.